San Antonio—Using standard heart failure pharmacotherapy during treatment with trastuzumab can prevent trastuzumab-induced cardiac toxicities, according to results from the MANTICORE 101 trial.
The study showed that in women with early breast cancer, angiotensin-converting enzyme (ACE) inhibitors and b-blockers protect against declines in left ventricular ejection fraction (LVEF) caused by trastuzumab and reduce treatment interruptions due to LV dysfunction. The drugs were not